Ticagrelor
Product Specifications
CAS Number
274693-27-5
Target
Cytochromes P450|||P2Y Receptor
Related Pathways
Metabolism|||Neuroscience|||GPCR/G Protein
Purity
>99.99%
Bioactivity
Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique (EU) and Possia (EU) .
Smiles
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
034577-ML550 100 µL
DEGS2, CT (DEGS2, C14orf66, Sphingolipid delta (4) -desaturase/C4-hydroxylase DES2, Degenerative spermatocyte homolog 2) (MaxLight 550) discontinued
Ask
View Details